Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in ...

Vertex Pharmaceuticals has caught investors’ eyes, but its stock performance isn’t exactly a mic-drop moment. Despite massive ...

Vertex Pharmaceuticals's VRTX short percent of float has risen 27.71% since its last report. The company recently reported ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Short interest in Vertex Pharmaceuticals jumped 27.5% in May, hitting 4.82 million shares—just under 2% of the float. This ...

SpyGlass Pharma announced today that it closed a $75 million Series D financing round to support its drug delivery platform.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Some investors are staying away from the market right now due to the volatility stocks have experienced this year and the ...

Vertex Pharmaceuticals Inc. closed 14.97% short of its 52-week high of $519.88, which the company achieved on November 8th.

Ailsa Craig and Marek Poszepczynski, portfolio managers at the International Biotechnology Trust, tell MoneyWeek where they’d ...

Four months after Vertex Pharmaceuticals Inc.’s U.S. FDA nod for Journavx (suzetrigine) as the first drug targeting NaV1.8 for treating pain, Eli Lilly and Co. is joining the potential competition via ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.